Nadia Veleva

Assoc. Prof. Nadia Veleva, PhD serves as an Associate Professor at the Department of Pharmaceutical Sciences and Social Pharmacy within the Faculty of Pharmacy at Medical University of Pleven, Bulgaria. Her academic career is deeply rooted in pharmaceutical economics and health policy analysis within the Bulgarian healthcare context.

Her research interests span Pharmaceutical Economics, Health Technology Assessment, Antimicrobial Resistance policy, and Cost-Effectiveness Analysis of advanced therapies. She maintains a strong focus on Bulgarian healthcare system challenges, particularly in drug reimbursement mechanisms and antibiotic stewardship programs. Her work consistently bridges theoretical economic models with practical policy implementation in Eastern European healthcare settings.

Analysis of her 15 most recent publications (2019-2024) reveals three dominant research trajectories: 1) Economic evaluations of targeted oncology therapies (comprising 40% of recent output), 2) Antimicrobial resistance policy frameworks in Bulgaria (30%), and 3) Methodological innovations in health technology assessment (30%). Her oncology work demonstrates exceptional depth in cost-effectiveness modeling for immunotherapies and antibody-drug conjugates, while her AMR research pioneers One Health approaches tailored to Bulgaria's healthcare infrastructure.

Though the source material contains no explicit mentions of scientific awards, her extensive publication record in high-impact pharmacoeconomic journals indicates significant scholarly recognition. Similarly, while advising activities aren't documented, her collaborative publication pattern across medical specialties suggests active mentorship roles within the university's research ecosystem.

Her departmental affiliation within the Faculty of Pharmacy positions her at the critical intersection of clinical pharmacy practice and health policy development. Current research appears focused on optimizing Bulgaria's pharmaceutical reimbursement system while addressing antimicrobial resistance through multi-sectoral collaboration frameworks.